Brickell Biotech Inc

Fresh Tracks Therapeutics, Inc. engages in the development of prescription therapeutics for the treatment of skin diseases. Its pipeline consists of new molecular entities targeting the treatment of the following indications: hyperhidrosis, allergic contact dermatitis, androgenic alopecia, cutaneous t-cell lymphoma and psoriasis. The company was founded by Reginald L. Hardy and Andrew D. Sklawer in 2009 and is headquartered in Boulder, CO.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Fresh Tracks Therapeutics, Inc. engages in the development of prescription therapeutics for the treatment of skin diseases. Its pipeline consists of new molecular entities targeting the treatment of the following indications: hyperhidrosis, allergic contact dermatitis, androgenic alopecia, cutaneous t-cell lymphoma and psoriasis. The company was founded by Reginald L. Hardy and Andrew D. Sklawer in September 2009 and is headquartered in Boulder, CO.

Fresh Tracks Therapeutics Inc

Meeting adjourned to December 15, 2023 at 10 a.m. MT

Fresh Tracks Therapeutics Announces Second Adjournment of Special Meeting of Stockholders

Meeting adjourned to November 30, 2023 at 10 a.m. MT Fresh Tracks encourages all stockholders of record on October 17, 2023 who have not yet voted to do so by 11:59 p.m.

Fresh Tracks Therapeutics Announces Adjournment of Special Meeting of Stockholders

Cash and cash equivalents of approximately $11.5 million as of October 31, 2023 Special meeting of stockholders on November 16 seeking stockholder approval of the Dissolution and Plan of Dissolution If approved by stockholders, the Company estimates that cash distributions in the Dissolution will be between $5 million and $7 million, or $0.84 to $1.17 per share, to stockholders BOULDER, Colo., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (the “Company” or “Fresh Tracks”) (Nasdaq: FRTX), today announced financial results for the third quarter ended September 30, 2023 and provided a corporate update.

Fresh Tracks Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Company intends to make cash distributions currently estimated to be between $5 million and $7 million, or $0.84 to $1.17 per share, to shareholders following shareholder approval and the filing of the certificate of dissolution Company intends to make cash distributions currently estimated to be between $5 million and $7 million, or $0.84 to $1.17 per share, to shareholders following shareholder approval and the filing of the certificate of dissolution

Fresh Tracks Therapeutics Announces Board Approval of Plan of Liquidation and Dissolution

Strengthened current cash position to approximately $15 million as of July 31, 2023 as a result of sale of future rights to event-based milestone and earnout payments on net sales of sofpironium bromide to Botanix SB Inc.

Fresh Tracks Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Strengthens cash position as Company continues to evaluate strategic options to maximize shareholder value Strengthens cash position as Company continues to evaluate strategic options to maximize shareholder value

Fresh Tracks Announces $8.25 Million Buyout of Its Right to Receive Future Sofpironium Bromide Payments from Botanix

Reported positive topline results from SAD and MAD parts of Phase 1 study of lead DYRK1A inhibitor FRTX-02 in March 2023

Fresh Tracks Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

Positive topline results from single and multiple ascending dose parts of the Phase 1 study of FRTX-02 support its continued development as a potential first-in-class, once-daily oral treatment for atopic dermatitis and/or other autoimmune diseases

Fresh Tracks Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

FRTX-02 was generally safe and well tolerated within the potential therapeutic dose range, meeting the study's primary objectives

Fresh Tracks Therapeutics Announces Positive Topline Results from Single and Multiple Ascending Dose Parts of Phase 1 Study of Oral DYRK1A Inhibitor FRTX-02

Rob Brown to continue serving as a member of the Board of Directors and as a special advisor to the Company Rob Brown to continue serving as a member of the Board of Directors and as a special advisor to the Company

Fresh Tracks Therapeutics Appoints Andrew Sklawer as Chief Executive Officer

Topline results from SAD and MAD parts of FRTX-02 Phase 1 study expected in Q1 2023 Topline results from SAD and MAD parts of FRTX-02 Phase 1 study expected in Q1 2023

Fresh Tracks Therapeutics Announces Publication of Preclinical Data for FRTX-02, a Potential First-in-Class Oral DYRK1A Inhibitor, in the Peer-Reviewed Journal of Translational Autoimmunity

Phase 1 study of FRTX-02 progressing well, with the SAD portion complete and MAD portion underway

Fresh Tracks Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

BOULDER, Colo., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (“Fresh Tracks Therapeutics” or the “Company”) (Nasdaq: FRTX), a clinical-stage pharmaceutical company aiming to disrupt existing treatment paradigms by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases, today announced that it will report its third quarter financial results on Thursday, November 10th. Company management will host a conference call and webcast at 4:30 p.m. EST that same day to discuss the financial results and recent corporate highlights.

Fresh Tracks Therapeutics to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on November 10, 2022

FRTX-02 has been well tolerated in completed SAD cohorts; dosing of remaining SAD cohorts to continue in parallel with MAD cohorts dosing

Fresh Tracks Therapeutics Initiates Multiple Ascending Dose Portion of Phase 1 Study of DYRK1A Inhibitor FRTX-02

New name, logo, website, and branding reflect the Company's strategic shift toward developing potentially groundbreaking autoimmune and inflammatory disease therapies

Brickell Biotech Announces Corporate Rebranding to Fresh Tracks Therapeutics

Brickell Biotech, Inc. (NASDAQ:BBI ) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Garth Russell - IR, LifeSci Advisors Robert Brown - Chief Executive Officer Monica Luchi - Chief Medical Officer Albert Marchio - Chief Financial Officer Deepak Chadha - Chief R&D Officer Conference Call Participants Ron Mather - Oppenheimer Thomas Flaten - Lake Street Operator Welcome everyone to the Brickell Biotech Second Quarter 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode.

Brickell Biotech, Inc. (BBI) CEO Robert Brown on Q2 2022 Results - Earnings Call Transcript

Phase 1 study of BBI-02 progressing well and expect to initiate MAD part of the study next month

Brickell Biotech Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Brickell (BBI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Brickell (BBI) Report Negative Earnings Next Week? What You Should Know

BOULDER, Colo., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases, today announced that it will report its second quarter financial results on Thursday, August 11th. Brickell's management will host a conference call and webcast at 4:30 p.m. EDT that same day to discuss the financial results and recent corporate highlights.

Brickell Biotech to Report Second Quarter 2022 Financial Results and Provide a Corporate Update on August 11, 2022

BOULDER, Colo., July 20, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases, today announced that it received formal notice from The Nasdaq Stock Market (“Nasdaq”) stating that Brickell has regained compliance with the minimum bid price requirement for continued listing on Nasdaq and, accordingly, the scheduled hearing has been canceled and Brickell's common stock will continue to be listed and traded on Nasdaq.

Brickell Biotech Regains Compliance with Nasdaq Minimum Bid Price Requirement

BOULDER, Colo., July 06, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases, today announced that its management team will participate in a fireside chat at the upcoming William Blair Biotech Focus Conference 2022, being held in New York on July 12 & 13, 2022.

Brickell Biotech to Participate at William Blair Biotech Focus Conference 2022

Brickell Biotech, Inc. (Nasdaq: BBI) announced a 1-for-45 reverse split. These are the details.

Brickell Biotech (BBI) Stock: 1-For-45 Reverse Split Announced

Common stock will begin trading on a split-adjusted basis on July 5, 2022 Common stock will begin trading on a split-adjusted basis on July 5, 2022

Brickell Biotech Announces 1-For-45 Reverse Stock Split

Delistings are commonplace in this bear market, however investors in Brickell Biotech and BBI stock are cheering some news today. The post Brickell Biotech (BBI) Stock Gains 50% Ahead of Meeting to Prevent Delisting appeared first on InvestorPlace.

Brickell Biotech (BBI) Stock Gains 50% Ahead of Meeting to Prevent Delisting

NeuroSense Therapeutics Ltd

Trevi Therapeutics Inc

Penny stocks to buy or avoid right now? You decide after seeing the latest updates from 3 companies.

News for Brickell Biotech Inc Stock (BBI)